Neuromuscular monitoring and the cost of antagonism: when will we learn?

S. J. Brull; R. C. Prielipp

doi:10.1111/anae.14111

Neuromuscular monitoring and the cost of antagonism: when will we learn?

S. J. Brull
, R. C. Prielipp

Anesthesiology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1557-1558
Number of pages	2
Journal	Anaesthesia
Volume	72
Issue number	12
DOIs	https://doi.org/10.1111/anae.14111
State	Published - Dec 2017

Bibliographical note

Funding Information:
No external funding declared. SB is a member of the Anesthesia Patient Safety Foundation (APSF) Board of Directors (Rochester, MN), has received research funding from Merck & Co., Inc. (Kenilworth, NJ) (funds to Mayo Clinic), is a principal and shareholder in Senzime AB (publ) (Uppsala, Sweden), and a member of the Scientific Advisory Boards for ClearLine MD (Woburn, MA), The Doctors Company (Napa, CA), and NMD Pharma (Aarhus, Denmark). RP is a member of the Anesthesia Patient Safety Foundation (APSF) Executive Committee and Board of Directors (Rochester, MN). Previously posted on the Anaesthesia correspondence website: www.anaes- thesiacorrespondence.com

Publisher link

10.1111/anae.14111

Find It

Find It at U of M Libraries

Cite this

@article{1645dc5a94734fe998a8a9db20564dd0,

title = "Neuromuscular monitoring and the cost of antagonism: when will we learn?",

author = "Brull, \{S. J.\} and Prielipp, \{R. C.\}",

note = "Funding Information: No external funding declared. SB is a member of the Anesthesia Patient Safety Foundation (APSF) Board of Directors (Rochester, MN), has received research funding from Merck \& Co., Inc. (Kenilworth, NJ) (funds to Mayo Clinic), is a principal and shareholder in Senzime AB (publ) (Uppsala, Sweden), and a member of the Scientific Advisory Boards for ClearLine MD (Woburn, MA), The Doctors Company (Napa, CA), and NMD Pharma (Aarhus, Denmark). RP is a member of the Anesthesia Patient Safety Foundation (APSF) Executive Committee and Board of Directors (Rochester, MN). Previously posted on the Anaesthesia correspondence website: www.anaes- thesiacorrespondence.com",

year = "2017",

month = dec,

doi = "10.1111/anae.14111",

language = "English (US)",

volume = "72",

pages = "1557--1558",

journal = "Anaesthesia",

issn = "0003-2409",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Neuromuscular monitoring and the cost of antagonism

T2 - when will we learn?

AU - Brull, S. J.

AU - Prielipp, R. C.

N1 - Funding Information: No external funding declared. SB is a member of the Anesthesia Patient Safety Foundation (APSF) Board of Directors (Rochester, MN), has received research funding from Merck & Co., Inc. (Kenilworth, NJ) (funds to Mayo Clinic), is a principal and shareholder in Senzime AB (publ) (Uppsala, Sweden), and a member of the Scientific Advisory Boards for ClearLine MD (Woburn, MA), The Doctors Company (Napa, CA), and NMD Pharma (Aarhus, Denmark). RP is a member of the Anesthesia Patient Safety Foundation (APSF) Executive Committee and Board of Directors (Rochester, MN). Previously posted on the Anaesthesia correspondence website: www.anaes- thesiacorrespondence.com

PY - 2017/12

Y1 - 2017/12

UR - https://www.scopus.com/pages/publications/85033477141

UR - https://www.scopus.com/pages/publications/85033477141#tab=citedBy

U2 - 10.1111/anae.14111

DO - 10.1111/anae.14111

M3 - Letter

C2 - 29130278

AN - SCOPUS:85033477141

SN - 0003-2409

VL - 72

SP - 1557

EP - 1558

JO - Anaesthesia

JF - Anaesthesia

IS - 12

ER -

Neuromuscular monitoring and the cost of antagonism: when will we learn?

Bibliographical note

Publisher link

Find It

Other files and links

Cite this